SA Firm Raises R85m to Scale AI Stethoscope for TB Screening

Why It Matters

Early, low‑cost TB detection can close South Africa’s diagnostic gap, reducing transmission and mortality, while showcasing a replicable model for AI‑driven health tools in low‑resource settings.

Key Takeaways

• AI Diagnostics raised ~R85 million ($4.6 M) for AI stethoscope rollout.
• Device detects TB via lung sounds, enabling point‑of‑care screening.
• Over 1,000 South Africans screened; trials span 10+ African and Asian nations.
• Funding supports clinical validation, AI model refinement, and scaling operations.
• Investors cite social impact and growth potential in point‑of‑care diagnostics.

Pulse Analysis

Tuberculosis remains a public‑health emergency in South Africa, where 249,000 new cases and 54,000 deaths were recorded in 2024. Traditional diagnostics rely on X‑ray and laboratory infrastructure that many high‑burden communities lack, leading to late‑stage detection and ongoing transmission. The WHO reports that 58% of TB‑positive individuals are asymptomatic, underscoring the need for innovative, symptom‑independent screening tools that can be deployed at the community level.

AI Diagnostics’ Ostium digital stethoscope tackles this gap by marrying a rugged handheld device with AI.TB software that interprets lung sounds in real time. The system has secured South African Health Products Regulatory Authority clearance and already screened more than a thousand patients, delivering immediate referral cues to nurses and community health workers. Ongoing trials across ten-plus countries in Africa and Asia aim to validate its accuracy against gold‑standard tests, while the latest funding round will expand manufacturing, data collection, and AI model training to improve sensitivity and specificity.

The $4.6 million infusion reflects a broader investor appetite for point‑of‑care AI medical devices that promise both health impact and commercial upside. Venture capital firms see AI Diagnostics as a template for scaling low‑cost diagnostics for other respiratory and cardiac conditions, potentially reshaping global medtech markets. As regulatory pathways mature and AI models become more robust, such solutions could accelerate the fifth industrial revolution in healthcare, delivering affordable, high‑quality diagnostics to underserved populations worldwide.